CJC-1295 + Ipamorelin Blend
How this combination works
CJC-1295 and ipamorelin target two independent GH secretion pathways simultaneously. CJC-1295 is a GHRH analogue that binds the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, triggering cAMP-mediated GH gene expression and secretion. Ipamorelin is a synthetic pentapeptide that binds the ghrelin receptor (GHS-R1a), a structurally and pharmacologically distinct receptor that signals via separate calcium-mobilising mechanisms. Because these two receptors signal through different intracellular pathways, co-activation is expected to produce additive or supra-additive GH pulse amplification. Human studies using related GHRH + GHRP class combinations — the mechanistic predecessors of this stack — have confirmed synergistic GH output in humans when a GHRH analogue and a GHRP-class compound are combined. Ipamorelin has also been proposed to suppress somatostatin tone (the endogenous GH brake), allowing the GHRH-driven component to generate a larger GH quantum. This rationale is mechanistic inference supported by class-level human evidence; no randomised controlled trial has directly tested the CJC-1295 + ipamorelin combination as of 2026-10-08.
Combined mechanism
When co-administered, CJC-1295 and ipamorelin simultaneously engage two distinct GH secretion pathways at the anterior pituitary. CJC-1295 occupies GHRH receptors on somatotroph cells, increasing intracellular cAMP and initiating GH release. With the DAC modification, the compound binds covalently to serum albumin (Cys34), extending its effective half-life to approximately 5.8–8.1 days. Without DAC (Mod GRF 1-29 form), the half-life is approximately 30 minutes — aligned with ipamorelin's ~2-hour terminal half-life. Ipamorelin occupies GHS-R1a (ghrelin receptor) on the same somatotroph cells, mobilising intracellular calcium through a pathway independent of cAMP. In preclinical models, combined GHRH-class + GHRP-class administration produces GH pulses substantially larger than either agent alone. A proposed additional mechanism is that ipamorelin — like other GHRP-class compounds — suppresses somatostatinergic inhibition, removing the brake on GH release and allowing a larger GH quantum from the GHRH-R–stimulated somatotroph. Downstream, the GH pulse drives hepatic IGF-1 synthesis. The anabolic, lipolytic, and tissue-repair effects sought in community use are attributed to this amplified GH/IGF-1 response. One animal study directly testing CJC-1295 + ipamorelin — the only such study found — showed significantly improved maximum tetanic tension in murine glucocorticoid-induced muscle loss. Timing variant: when the without-DAC form is used, both compounds can be mixed in the same syringe and injected simultaneously, producing co-activation of both receptor pathways within the same GH pulse window.
What each component does
Two distinct forms are in community use: CJC-1295 with DAC (Drug Affinity Complex, ~8-day half-life, dosed once weekly) and CJC-1295 without DAC / Mod GRF 1-29 (~30-min half-life, dosed multiple times daily). Community stack protocols for this blend predominantly use the without-DAC form, which shares an injection window with ipamorelin and is commonly co-injected. Some protocols use the DAC form on a separate weekly schedule alongside daily ipamorelin.
View full peptide page →IpamorelinView full peptide page →Community dosing protocols
All protocols below are community-reported. No clinical dosing guidelines exist for this combination.
| Goal / context | CJC-1295 without DAC (Mod GRF 1-29) | Ipamorelin | Frequency | Duration | Notes |
|---|---|---|---|---|---|
| Conservative GH pulse amplification for body composition improvement, recovery, and sleep quality commonly reported | 100 mcg subcutaneous injection pre-sleep, co-injected with ipamorelin | 200 mcg subcutaneous injection pre-sleep, co-injected with CJC-1295 without DAC | once daily, pre-sleep | 8–12 weeks | CJC-1295 without DAC + ipamorelin at conservative doses. Pre-sleep timing is chosen to coincide with the natural nocturnal GH pulse. Same-syringe co-injection is widely reported as the standard preparation method. Consistently described as an entry-level protocol for this stack. |
| Standard GH pulse optimization for muscle gain, fat loss, and recovery commonly reported | 300 mcg subcutaneous injection pre-sleep, co-injected with ipamorelin | 300 mcg subcutaneous injection pre-sleep, co-injected with CJC-1295 without DAC | once daily, pre-sleep | 8–12 weeks | The 300 mcg + 300 mcg dose is described across community sources as the 'classic' or 'standard' CJC + Ipamorelin stack. Community users frequently note injecting on an empty stomach and waiting 20–30 minutes before eating to maximize GH pulse amplitude; no clinical evidence supports this specific practice. |
| Maximum GH axis stimulation via multiple daily pulses for body recomposition commonly reported | 100–300 mcg per injection subcutaneous injection morning (fasted), post-workout, and pre-sleep — three separate injections | 200–300 mcg per injection subcutaneous injection co-injected with CJC-1295 without DAC at each of the three daily injection times | three times daily (morning fasted, post-workout, pre-sleep) | 8–12 weeks | Multi-pulse protocol reported primarily by advanced users. Three-times-daily injections produce continuous GH axis stimulation throughout the day. Total daily doses are cumulative (3× per-injection amounts). Not recommended for beginners. Same fasted-injection and post-injection timing notes apply as in single-daily protocols. |
| Sustained GH elevation via long-acting CJC-1295 with DAC, plus daily acute GH pulse enhancement via ipamorelin, for longevity, body composition, and recovery commonly reported | — | 200–300 mcg subcutaneous injection once daily pre-sleep (separate schedule from CJC-1295 with DAC) | CJC-1295 with DAC: once weekly. Ipamorelin: once daily pre-sleep. | 12–24 weeks | The only protocol variant using the DAC form of CJC-1295. Because the two compounds have very different half-lives in this variant, they are injected on separate schedules rather than co-injected. The DAC form provides a persistent elevated GH/IGF-1 baseline; daily ipamorelin adds acute pulse amplification on top. Discussed primarily in anti-aging and TRT community contexts. This variant is expected to produce more sustained IGF-1 elevation than the without-DAC protocols. |
Most reported: 100–300 mcg per injection (without DAC / Mod GRF 1-29) or 1000 mcg once weekly (with DAC) CJC-1295 + 200–300 mcg per injection Ipamorelin · Once daily pre-sleep (standard protocol); three times daily (advanced multi-pulse) · 8–12 weeks
Evidence base for this combination
- Mayfield CK et al. Am J Sports Med. 2026.ANIMAL COMBINATION PMID 41476424
The only study found that directly tests the CJC-1295 + ipamorelin pairing. CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in a murine model of glucocorticoid-induced muscle loss. Findings are limited to animals; no human efficacy or safety data for this specific combination exists in the reviewed literature.
- Veldhuis JD et al. J Clin Endocrinol Metab. 2002.HUMAN CLASS EVIDENCE PMID 11836333
Human study of combined GHRH(1-44) + GHRP-2 administration demonstrating synergistic GH pulse amplification when a GHRH analogue and a GHRP-class compound are co-administered. Class-level evidence supporting the dual-pathway rationale. The specific agents studied (GHRH + GHRP-2) differ from CJC-1295 + ipamorelin; findings cannot be directly transferred but provide mechanistic plausibility for human synergy.
- Iranmanesh A et al. J Clin Endocrinol Metab. 2004.MECHANISTIC PMID 15356066
Mechanistic study documenting that GHRP-class compounds suppress somatostatin tone, providing the proposed explanation for the amplified GH output when a GHRH analogue and a GHRP are combined. Does not test CJC-1295 or ipamorelin directly.
- Dominikowski et al. Front Endocrinol. 2026.REVIEW MENTION PMID 42395176
Review article explicitly names CJC-1295 + ipamorelin as a specific combination used in performance enhancement and anti-aging contexts. Documents community co-use; does not provide efficacy or safety outcome data for this pairing.
Safety considerations for this combination
- No human combination-specific safety data exists for CJC-1295 + ipamorelin. Human data for each component are derived from independent short-term studies. Long-term safety of the combination in humans is entirely unknown. PMID: 41966639, 42021992
- Compounded IGF-1 elevation: both CJC-1295 and ipamorelin independently stimulate GH release, and co-activation of two independent GH secretion pathways is expected to produce greater IGF-1 elevation than either compound alone. Chronically supraphysiological IGF-1 carries biologically plausible but unstudied mitogenic risk. Mechanistic inference from dual-pathway GH stimulation; PMID: 42395176
- Compounded glycaemic effects: GH excess can induce insulin resistance (a class effect of GH-axis activation), while ipamorelin in vitro stimulates pancreatic insulin secretion (PMID: 15665799). The net effect on glucose homeostasis from combined use in humans is unpredictable and has not been studied. Ipamorelin in vitro glycaemic data: PMID: 15665799; GH-driven metabolic effects: PMID: 42395176
- Class-wide adverse effects for GH-axis secretagogues include prolactin and cortisol elevations, appetite changes, dysglycaemia, fluid retention (oedema), myalgia/arthralgia, and injection-site reactions. These risks are likely at least additive when two GH-axis compounds are combined. Inherited from CJC-1295 and Ipamorelin; PMID: 42395176
- Cardiovascular strain, insulin resistance, dyslipidaemia, and psychiatric instability are described as emerging class-level risks for GH secretagogue use, particularly with supraphysiological or combined protocols. Combination use of two GH-axis agents may increase these risks compared to either compound alone; no combination-specific data exist. PMID: 41880199
- Gray-market product quality risk: both CJC-1295 and ipamorelin are commonly sourced through unregulated channels. Mislabelling, contamination, and analog substitution (e.g., Gly-Ipamorelin) have been documented for ipamorelin; illicit CJC-1295 preparations have been seized by law enforcement. Pre-blended vials combining both compounds introduce additional uncertainty about actual per-component doses. CJC-1295: PMID: 21204297, 42395176; Ipamorelin: PMID: 29864719, 30136411
Contraindications
- Competitive athletes are contraindicated from using both CJC-1295 and ipamorelin. Both compounds are prohibited by the World Anti-Doping Agency (WADA) under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Use by competing athletes carries significant anti-doping consequences. Inherited from CJC-1295 (PMID: 41138283); inherited from Ipamorelin (PMID: 26578461)
- Neither CJC-1295 nor ipamorelin has been approved by any regulatory authority for performance enhancement or general clinical use. The combination has not been evaluated in any human clinical trial. The absence of established contraindications in the reviewed literature reflects a lack of clinical evaluation, not established safety. Inherited from CJC-1295 (PMID: 41966639); inherited from Ipamorelin (PMID: 41966639, 42160466)
- Individuals with diabetes mellitus may experience unpredictable GH hypersecretion in response to ipamorelin, as demonstrated in streptozotocin-diabetic animal models. Combined use with CJC-1295 may compound this unpredictability. No human data exists to quantify this risk for the combination. Inherited from Ipamorelin (PMID: 14630569); extrapolation to combination is mechanistic inference